Glen Elliott, MD, PhD

From Infantile Autism to Autism Spectrum Disorder

January 1, 2017

Glen Elliott, MD, PhD Editor-in-chief, The Carlat Child Psychiatry Report Dr. Elliott has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Changes in diagnostic criteria not only affect the clinical and public perception of a disorder, but also its perceived prevalence. Such is the case with autism. The evolution of the autism diagnosis since it was introduced into the Diagnostic and Statistical Manual (DSM) in 1980 inarguably has altered its reported prevalence.

Concerta: Brand vs Generic

January 1, 2017

Glen Elliott, MD, PhD

Glen Elliott, MD, PhD Editor-in-chief, The Carlat Child Psychiatry Report

In November 2016, the FDA announced that it was requiring two companies to withdraw their generic versions of Concerta (OROS methylphenidate) because of efficacy concerns. Such actions are quite unusual, and when they occur, they tend to shake doctors’ confidence in the generic drug system—which branded drug companies are often eager to encourage. But the Concerta case is hardly an indictment of generic drugs, or even of generic stimulants. Let’s dig a little deeper for some insight into the generic drug process.

Using Antipsychotics Judiciously in Children

December 1, 2014

Glen Elliott, MD, PhD

Glen R. Elliott, MD, PhD
Chief Psychiatrist and Medical Director Children’s Health Council, Palo Alto, CA. Clinical Professor (Affiliated), Stanford University School of Medicine, Division of Child and Adolescent Psychiatry.
Dr. Elliott has disclosed that he has no relevant relationshipt or financial interests in any commercial company pertaining to this educational activity.

Read about the appropriate use of antipsychotics to treat disorders in children and adolescents, in an interview with psychiatrist Glen R. Elliott, MD, PhD.